HB1801 Combined Treatment of HER2-positive Breast Cancer

NCT07116824 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

80

Enrollment

INDUSTRY

Sponsor class

Conditions

HER2-positive Breast Cancer

Interventions

DRUG: HB1801
DRUG: Trastuzumab
DRUG: Pertuzumab
DRUG: Docetaxel

Sponsor

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.